Loading stock data…
$2.15-0.04 (-1.60%)
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States.
Ovid Therapeutics Inc. in the Healthcare sector is trading at $2.15 with a market capitalization of $537M. Wall Street consensus targets $6.02 (10 analysts), implying a +179.5% move over the next 12 months. The stock is currently 31% below its 52-week high of $3.10, remaining 7.1% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $733,000 | $0↓ | $718,000↑ | $132,000↓ | $6.27M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$15.70M↑ | -$17.85M↓ | -$12.29M↑ | -$12.52M↓ | -$5.07M |
| Net Income | -$15.01M↑ | -$16.99M↓ | $9.66M↑ | -$12.16M↓ | -$4.68M |
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a G...